Latest Blog Posts Tagged "Alpha-Synuclein"
January 12, 2018
Michael J. Fox Foundation-funded researchers have created exquisitely sensitive antibodies that may help test therapies against a top Parkinson's drug target.
June 23, 2017
Researchers have developed a tool to predict cognitive decline in PD for use in designing clinical studies. The team analyzed data from multiple studies including PPMI.
May 25, 2016
Today the Foundation announced funding for two projects leveraging the promise of engineered stem cells to speed new therapies and deeper understanding of Parkinson's disease.
May 29, 2015
Earlier this year MJFF launched two programs investigating the unknowns around alpha-synuclein, our most promising target for a disease-modifying therapy.
June 13, 2014
A new study shows two avenues through which inhibiting the function of the protein LRRK2 may help treat people with Parkinson's, even those without a LRRK2 genetic mutation.
March 20, 2014
Journalist Jon Palfreman's book detailed a discovery that forever changed the face of Parkinson's research. Years later, Palfreman himself was diagnosed with Parkinson's disease.
November 01, 2013
Theoretically, if a study's outcome is true, the same set-up would lead to the same results.
September 13, 2013
The MJFF Research Tools Program recently marked some milestones in the ongoing effort to strategically grow the MJFF tools catalogue and improve understanding of current tools and their utility.
July 05, 2013
The Foundation is devoting significant resources toward the development and distribution of LRRK2 antibodies, lab 'ingredients' to help scientists better study biological processes at work in PD.
July 01, 2013
In an effort to advance research and collaborate toward a cure, the Foundation is pioneering an innovative approach to accelerate drug development around the LRRK2 gene.